Abstract PS16-35: Microbiota and breast cancer in mexican women

• Published in: Cancer research (Chicago, Ill.) Ill.), 2021-02, Vol.81 (4_Supplement), p.PS16-35-PS16-35
• Main Authors: Valdés, Arely Berenice González, Rocha, Juan Enrique Bargallo, Castro, Juan Manuel Medina, Plasencia, Carlos Pérez, Catalan, Oliver Millan, Pérez, Elvia Fernández, Martinez, Antonio Daniel, De León, David Cantú
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.SABCS20-PS16-35

Microbiota and breast cancer in Mexican womenStudy Type: ObservationalTime Perspective: Cross-SectionalThe human microbiome refers to the genes of the universe of microbes that inhabit our skinand mucosal surfaces. Epidemiological studies implicated that human microfloracontributes to 16% more of malignant neoplasms worldwide, either as a risk factor orcausative agent.Although hereditary and genetic factors represent 5% to 10% of breast cancer cases, 70%of them are due to a host of environmental factors. Migrant studies demonstrated that non-hereditary factors are the main drivers of international and inter-ethnic differences in theincidence and mortality of breast cancer. The environment contributes to the developmentof the disease; although, the factors involved are not well known, among the latter is theinfluence of microorganisms and, therefore, attention is recently being paid to themammary microbiota. This study hypothesizes that women with breast cancer havedifferences in the composition and functionality of breast microbiota compared to womenwithout breast disease.Inclusion and exclusion criteria. Women's age range of 25-70 years. Women with confirmedbreast cancer diagnosis scheduled for surgery as primary treatment (mastectomy orconservative surgery) surgically intervened with breast augmentation or reduction withoutbreast cancer and signed informed consent. Women with antecedents of cancer, or whohave received antibiotic treatment one month before recruitment, or any neoadjuvanttherapy, without breast surgery in the past for any reason. Immunocompromised patients.Pregnant patients or with the use of implants were excluded from the study.Sample size. Sixty women with confirmed breast cancer matched with 30 women withoutcancer, and 30 with benign breast disease. Three hospitals participated in the recruitment:Instituto Nacional de Cancerología, Centro Oncológico Estatal ISSEMYM and Centromedico ABC.Method: DNA total of tissue samples was extracted using the Quick-DNA Miniprep Plus Kit(Zymo research Cat. D4068). 5 uL of DNA isolated of tissue samples were amplified with16S™ Metagenomics Kit (Thermo Fisher Scientific, Cat. A26216) and were marked with IonXpress Barcode Adapter (Thermo Fisher Scientific cat. no. 4471250), purified with AMPureXP reagent (Beckman Coulter cat. no. A63881) and quantified with Ion Universal LibraryQuantitation Kit (Thermo Fisher Scientific cat. no. A26217). After that, emulsion PCR wasprepared in the Ion OneTouch 2 System